Failure to adhere to medication regimen · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse event · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in adverse event compared with sulfasalazine (moderate certainty).
1 finding from 1 review
Pain reduction ‐ not measured · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Function ‐ not measured · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Tophus regression · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Allopurinol 100‐300 mg daily showed no clear difference in withdrawal due to adverse effects compared with febuxostat 80 mg daily (moderate certainty).
1 finding from 1 review
Serious adverse effects · people with chronic gout
Allopurinol 100‐300 mg daily showed no clear difference in serious adverse effects compared with febuxostat 80 mg daily (moderate certainty).
1 finding from 1 review
Acute gout attacks · people with chronic gout
Allopurinol 100‐300 mg daily showed no clear difference in acute gout attacks compared with febuxostat 80 mg daily (low certainty).
1 finding from 1 review
Proportion achieving target serum urate · people with chronic gout
Allopurinol 100‐300 mg daily may leads to lower proportion achieving target serum urate compared with febuxostat 80 mg daily (low certainty).
1 finding from 1 review
Mortality Clinically · people with hepatic encephalopathy
Branched‐chain amino acids (BCAA) showed no clear difference in mortality Clinically compared with control (moderate certainty).
1 finding from 1 review
Hepatic encephalopathy · people with hepatic encephalopathy
Branched‐chain amino acids (BCAA) leads to lower hepatic encephalopathy Psychometric and clinical assessments compared with control (high certainty).
1 finding from 1 review
Nausea and diarrhoea Clinically · people with hepatic encephalopathy
Branched‐chain amino acids (BCAA) showed no clear difference in nausea and diarrhoea Clinically compared with control (low certainty).
1 finding from 1 review
Albumin Laboratory assessment · people with hepatic encephalopathy
1 finding from 1 review
Nitrogen balance Laboratory assessment · people with hepatic encephalopathy
1 finding from 1 review
Disability due to FAP progression Not measured · people with TTR‐FAP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severity of peripheral neuropathy (expressed as the change in mNIS+7Ionis) Scale from: ‐22.3 (normal) to 346.3 (total impairment) · people with TTR‐FAP
1 finding from 1 review
QoL · people with TTR‐FAP
1 finding from 1 review
Has died · people with TTR‐FAP
Inotersen showed no clear difference in number of participants who died during the trial compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with TTR‐FAP
Inotersen may leads to higher number of dropouts due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Number of participants experiencing at least one severe adverse event · people with TTR‐FAP
Inotersen showed no clear difference in number of participants experiencing at least one severe adverse event compared with placebo (low certainty).
1 finding from 1 review